K. Schoeters,Overcoming The Misconceptions Of ContinuousProcessing, PTE article February 20114. Elaine Morefield PhDO Continuous Manufacturing in the Pharmaceutical Industry- An FDA Perspective, NDQA/CDER/FDA ISPE Annual Meeting, November 20095. Taraa Gooen, Office of compliance FDA/CDER, ISPE Annual Meeting, November 20096. Taraa Gooen, A scientific and Regulatory Perspective: Continuous Manufacturingand cGMP, FDA Continuous Manufacturing Symposium , March 20107. K. Schoeters ,Continuous Tableting: FromPowder to Tablet in 20 Minutes,innovations in Pharmaceutical Technologywww.iptonline.com8. Guidance for Industry, PAT - A Framework for Innovative PharmaceuticalDevelopment,Manufacturing, and Quality Assurance, USFood and Drug Administration, September 2004,9. www.ipqpubs.com/news/fda-touting-benefits-ofcontinuous-manufacturingFORMULATION OPTIMIZATION OF KETO-PROFEN HYDROPHILIC MATRIX SYSTEM BYUSING FACTORIAL EXPERIMENTAL DESIGN H. Litovin, R. Dameska, D. Dimova, E. Adamova, A. Sekovanic, E Ristevska, M. Anevska, D. Lepcevska, L. Ivceska, E. Dimitrovska, L. MakraduliReplekfarm, Kozle 188, 1000 Skopje, R. Macedonia INTRODUCTIONKetoprofen is a non-steroidal anti-inflammatory drug (NSAID), widelyused in order to reduce pain and inflammation caused by several con-ditions such as osteoarthritis, rheumatoid arthritis and abdominalcramps associated with menstruation. The mechanism of action ofketoprofen is mainly associated to the inhibition of the body's abilityto synthesize prostaglandins [1]. Conventional dosage forms of thisdrug, administered orally, are rapidly and almost completely absorbedfrom the gastro-intestinal tract, the peak plasma concentrations oc-curring within 1-3 h. Ketoprofen is an appropriate model drug for for-mulation of controlled release dosage forms due to its short plasmaelimination half-life and poor solubility, which affects its bioavailabil-ity. In recent years, the use of hydrophilic polymers, in particular cel-lulose derivatives, has attracted considerable attention for thedevelopment of controlled release technology in the formulation ofpharmaceutical products, due to their ability to form gels in aqueousmedium [2]. OBJECTIVEThe main objective of this study was to use a factorial experimentaldesign to study the influence of cellulose polymer (type and concen-tration) on the in vitro release profile of ketoprofen from hydrophilicpolymer matrices and formulation optimization by using response-sur-face methodology (RSM).MATERIALS AND METHODS Ketoprofen(Wuxue Xunda Pharmaceutical Co.,China); hydroxypropyl-methylcellulose HPMC 4000 (MethocelOK4M, Colorcon, West Point PA)and HPMC 100 (MethocelOK100 LV, Colorcon, West Point PA); hydrox-292Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOyethylcellulose HEC (NatrosolO250 HHX, Aqualon, Germany), lactosemonohydrate (TablettoseO80, Meggle GmbH, Germany), colloidal sili-con dioxide, anhydrous (AerosilO200, Evonic Industries, Germany), talc(Merck, Germany) and magnesium stearate (Mosselman, Belgium). Hy-drophilic matrices were prepared by wet granulation. Dissolution testwas performed according to USP/NF: apparatus 2 - paddle; medium -buffer solution with pH 7.2; volume - 1000 ml; velocity of mixing - 100rpm. Samples were analyzed by UV spectrophotometric determina-tion, absorbance wavelength 258 nm. Specification requirementswere: max. 25% after 1 h; 20 - 40% after 3 h, 35 - 55% after 6 h, min.55% released ketoprofen after 8 h.The factorial design was carried out by the software StatgraphicsO-plus (Version 5.1, USA).RESULTS AND DISCUSSIONThe influence of independent variables (type and concentration of cel-lulose polymer) was examined by achieving controlled release of ke-toprofen according to specified requirements. Independent variableswere varied on two levels (coded as 1 and 0) which represented addi-tion or absence of HPMC in the hydrophilic matrix formulation. Asshown on table 1, experimental combination 0/0 represents absenceof both HPMC polymers and presence of HEC. Table 1. Coded and real values for independent variables The data obtained from the statistical analysis of variance (ANOVA),show that the factors with the biggest influence on the release profileof the active ingredient were: the type of polymer (HPMC 4000 andHPMC 100) and interaction between the polymers (HPMC 4000 / HPMC100). From the responses at every stage of the dissolution profile canbe seen that all experimental combinations fulfill the criteria for therelease of ketoprofen in the 1st and the 4th stage of dissolution profile.Only, formulation containing combination of two cellulose polymers:HPMC 4000 / HPMC 100 release the ketoprofen in the 2nd and the 3rdstage within dissolution profile specified limits. Formulation opti-mization was made by combining multiple responses from all fourstages of the dissolution profile, as shown on the contour graphic plot(Fig. 1). Solid painted part (upper right corner) on the contour plot(Fig. 1) represents optimal formulation with: 14% w/w HPMC 4000 and16% w/w HPMC 100.Fig. 1. Contour plot of multiple optimizationThe tri-dimensional graph of the surface response (Fig. 2) shows theoptimal formulation with respect to d-function. Maximum value ob-tained for d-function is 0.9 for optimal responses: 10%; 25%; 48% and64% released ketoprofen after 1, 3, 6 and 8 hours, respectively. Fig. 2. Response-surface graphic plot showing optimal concentrationof hydrophilic polymers which influenced the release of ketoprofenfrom hydrophilic matrix system CONCLUSIONBy using 22 factorial experimental statistical design, the influence ofthe type and concentration of hydrophilic polymer on dissolution pro-file of ketoprofen were examined. Response surface graphs were usedand the optimal formulation with ketoprofen release profile accord-ing to specified dissolution profile was selected. REFERENCES1. Parfitt K. (eds). Martindale: The complete Drug reference 36th ed. ThePharmaceutical Press, London, 20092. Habib M.J., Mesue R. Development of controlled release formulations ofketoprofen for oral use. Drug Dev Ind Pharm 1995; 21:1463-1293Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONOPTIMIZATsIJA NA FORMULATsIJA NA KETOPROFEN KhIDROFILENMATRIKS SISTEM SO PRIMENA NAFAKTORIJALEN EKSPERIMENTALENSTATISTIChKI DIZAJN Kh. Litovin, R. Dameska, D. Dimova, E. Adamova, A.Sekovanikj, E Ristevska, M. Anevska, D.Lepchevska, L. Ivcheska, E Dimitrovska, L.MakraduliReplekfarm, Kozle 188, 1000 Skopje, R. MakedonijaVOVEDAktivnata supstantsija ketoprofen pripagja vo grupata nanesteroidni antiinflamatorni lekovi - NSAIL i se primenuva voterapijata na bolka i vospalenie predizvikani od slednitepatoloshki sostojbi: osteoartritis, revmatiden artritis istomachni grchevi vo menstrualnite periodi. Osnovniot mekhanizamna deluvanje na ketoprofenot e inkhibitsija na sintezata naprostaglandini [1]. Ketoprofenot formuliran vo konventsionalnafarmatsevtska dozirana forma, po peroralna administratsija brzoi kompletno se absorbira vo GIT, postignuvajkji maksimalnaplazma kontsentratsija za 1 - 3 h. Kratkoto poluvreme na eliminatsijai slabata rastvorlivost na ketoprofenot vlijaat na negovatabioraspolo-zhivost, a ottuka sozdavaat i pogoden kandidat zaformuliranje vo dozirana forma so prodolzheno osloboduvanje.Vo poslednite godini evidentna e se pogolemata upotreba nakhidrofilni polimeri, osobeno tseluloznite derivati, vo razvojotna formulatsii so prodolzheno oslobo-duvanje na aktivnatasupstantsija [2]. TsELOptimizatsija na formulatsijata na khidrofilen matriks sistem soprodolzheno osloboduvanje na ketoprofen so primena na faktori-jalen eksperimentalen statistichki dizajn.MATERIJAL I METODIKetoprofen (Wuxue Xunda Pharmaceutical Co., China); khidroksi-propil metil tseluloza HPMC 4000 (MethocelO K4M) i HPMC 100(MethocelO K100 LV, Colorcon, West Point PA); khidroksietil tselulozaHEC (NatrosolO 250 HHX, Aqualon, Germany) laktoza monokhidrat(Meggle GmbH, Germany), silitsium dioksid koloiden, bezvoden(AerosilO 200, Evonic Industries, Germany), talk (Merck, Germany) imagnezium stearat (Mosselman, Belgium). Khidrofilnite matrikstableti bea prigotveni so metod na vlazhna granulatsija. Testovitena disolutsija (spored USP/NF): aparat 2 - metod so veslo; vo puferso pH 7.2; volumen 1000 ml, 100 rpm, a primerotsite beaanalizirani so UV spektrofotometrisko otchituvanje na 258 nm.Spetsifikatsija za rastvorlivost: maks. 25% po 1 h; 20 - 40% po 3 h,35 - 55% po 6 h, min. 55 % po 8 h.Statistichkata obrabotka na podatotsite beshe izvrshena so primenana Statgraphics plus, Windows software program (Version 5.1, USA).REZULTATI I DISKUSIJAVlijanieto na tipot i kontsentratsija na khidrofilen polimer beshesogledano vo nasoka na postignuvanje na prodolzheno oslo bo du -vanje na ketoprofen vo ramkite na zadadenata spetsifikatsija.Nezavis-nite varijabli bea varirani na dve nivoa (kodirani kako1 i 0) shto oznachuva prisustvo ili otsustvo na HPMC voformulatsijata. Kako shto mozhe da se zabelezhi od tabelata 1,eksprimentalnata kombinatsija 0/0 se odnesuva na otsustvo na dvataHPMC polimeri, a prisustvo na HEC. Tabela 1. Kodirani i realni vrednosti na varijabliteSpored izvrshenata analiza na varijansa (ANOVA), statistichkiznachajno vlijanie imaat dvata faktori (HPMC 4000 i HPMC 100) iinteraktsijata pomegju niv (HPMC 4000 / HPMC 100) vrzdisolutsiskiot profil na ketoprofen. Optimizatsija na formulatsijata, zemajkji gi vo predvid chetiritefazi na disolutsija, prikazhana e kako konturen dijagram na slika 1.Slika 1. Konturen dijagram na multipna optimizatsijaNa grafichkiot prikaz oboeniot del (vo gorniot desen agol) japretstavuva optimalnata formula-tsija sostavena od 14% m/mHPMC 4000 i 16% m/m HPMC 100. Na slika 2 grafichki e prikazhanaoptimalnata formulatsija vo zavisnost od d-funktsijata.Najvisokata vrednost na d-funktsijata e 0.9 za optimalnitevrednosti na odgovorot po izminati 1, 3, 6 i 8 chasa: 10%; 25%; 48%i 64% osloboden ketoprofen, soodvetno. Slika 2. Response-surface grafichki prikaz na optimalnitekontsentratsii na khidrofilnite polimeri koi uslovuvaat dobi va njena matriks sistem so spetsifitsiraniot profil na osloboduvanje294Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOZAKLUChOKSo primena na 22 faktorijalen eksperimentalen statistichkidizajn sogledano e vlijanieto na tipot i kontsentratsijata nakhidrofilnite polimeri vrz brzinata na oslobo-duvanje naketoprofen, a voedno e selektirana i optimalnata formu-latsijachij disolutsiski profil odgovara na zadadenata spetsifi-katsijaza fazna rastvorlivost. LITERATURA1. Parfitt K. (eds). Martindale: The complete Drug reference 36th ed. Thepharmaceutical Press, London, 20092. Habib M.J., Mesue R. Development of controlled release formulations ofketoprofen for oral use. Drug Dev Ind Pharm 1995; 21:1463-14FORMULATION AND EVALUATION OF SOLIDLIPID NANOPARTICLES LOADED WITHBUDESONIDE FOR DELIVERY TO THE IN-FLAMED COLONIC MUCOSAH. Litovin, K. Goracinova, N. Geskovski, M. Simono-ska Crcarevska, S. Dimcevska, K. Mladenovska, M.Glavas DodovFaculty of Pharmacy, Ss Cyril and Methodius University, Vodnjanska17, 1000 Skopje, MacedoniaINTRODUCTIONUlcerative colitis and Crohn's disease are the major forms ofinflammatory bowel disease (IBD), characterized by chronicuncontrolled inflammation of intestinal mucosa. BDS, a potentcorticosteroid designed to have location specific delivery to the GIT,is one of the most used drugs in the treatment of active IBD.However, standard treatment for IBD necessitates the frequent intakeof anti-inflammatory drugs, leading to significant adverse events.Therefore, a carrier system able to deliver the drug specifically andexclusively to the inflamed regions for prolonged periods of time afteroral administration, would be a distinct improvement on the existingdelivery systems and would result in significantly fewer side effectscompared to conventional therapy (1). Solid lipid nanoparticles (SLNs) are under extensive worldwide study aspromising alternative drug carriers. SLNs are produced frombiocompatible and biodegradable lipid materials, making them apromising therapeutic strategy for drug targeting and delivery. Due totheir versatility in loading both lipophilic and hydrophilic molecules inthe solid lipid matrix, SLNs depict the ability to prolong, extend orsustain the release of the loaded molecules, therefore reducing therepeated administration, and increasing the therapeutic value of acertain treatment (2).The aim of this work was to design BDS loaded SLNs with physic oc he -mical and biopharmaceutical properties that will be in favor ofefficient local treatment of IBD after peroral administration. MATERIALS AND METHODSMATERIALSCutina GMS V PHO was kindly donated from Cognis, Germany. LipoidS100O and sodium glycocholate (Nagch) was gifts from Lipoid,Germany and New Zealand Pharm. Lim., respectively. TweenO 20 wasobtained from Merck, Germany. Budesonide (BDS) was purchased fromCrystal Pharma, Spain and EudragitO S 100 was supplied from Evonik,Germany. All other reagents were of analytical grade purity. PREPARATION OF BDS-SLNSSLNs were prepared by melt emulsification method using high-shearrotor-stator homogenization (7 min, 24000 rpm; Ultra-turraxO T18, Ika-Werke, Germany). Formulation optimization was performed usingresponse surface methodology (i.e.